NeoGenomics (NEO) Tops Q4 Earnings Estimates
NeoGenomics (NEO) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to earnings of $0.03 per share a year ago.
NeoGenomics Is On The Upswing, Reversing A CEO-Tied Sell-Off, On Bullish Long-Term Guidance
NeoGenomics stock jumped Wednesday after the company issued a strong 2025 outlook. That partially reversed a recent selloff.
NeoGenomics (NEO) Surges 9.1%: Is This an Indication of Further Gains?
NeoGenomics (NEO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
NeoGenomics (NEO) Upgraded to Buy: Here's Why
NeoGenomics (NEO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Airbus says A330NEO jet China certification progressing smoothly
The head of Airbus China said on Tuesday that the certification for its A330NEO plane in China was going smoothly and that the first delivery in the country could come in 2025.
NeoGenomics (NEO) Upgraded to Strong Buy: Here's What You Should Know
NeoGenomics (NEO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
NeoGenomics, Inc. (NEO) Q3 2024 Earnings Call Transcript
NeoGenomics, Inc. (NASDAQ:NEO ) Q3 2024 Earnings Conference Call November 5, 2024 8:30 AM ET Company Participants Kendra Sweeney - Vice President, Investor Relations and ESG Chris Smith - Chief Executive Officer Jeffrey Sherman - Chief Financial Officer Warren Stone - Chief Commercial Officer Kareem Saad - Head, Strategy and Transformation Andrew Lukowiak - Chief Innovation Officer Nate Montgomery - Vice President, Medical Services Melody Harris - Chief Operations Officer and President, Informatics Conference Call Participants Andrew Brackman - William Blair David Westenberg - Piper Sandler Mike Matson - Needham & Company Matthew Hewitt - Craig-Hallum Capital Group Prashant Kota - Goldman Sachs Mark Massaro - BTIG Mason Carrico - Stephens, Inc. John Kim - Bank of America Andrew Cooper - Raymond James Puneet Souda - SVB Leerink Operator Welcome to the NeoGenomics Third Quarter 2024 Financial Results Conference Call and Webcast. At this time, all participants are in a listen-only mode.
NeoGenomics (NEO) Reports Q3 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for NeoGenomics (NEO) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Wall Street Analysts Believe NeoGenomics (NEO) Could Rally 51.29%: Here's is How to Trade
The consensus price target hints at a 51.3% upside potential for NeoGenomics (NEO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
NeoGenomics (NEO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
NeoGenomics (NEO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
NeoGenomics Inc (NEO) Shares Up 3.95% on Oct 2
Shares of NeoGenomics Inc (NEO, Financial) surged 3.95% in mid-day trading on Oct 2. The stock reached an intraday high of $14.36, before settling at $14.36, up from its previous close of $13.81.
NeoGenomics, Inc. (NEO) Q2 2024 Earnings Call Transcript
NeoGenomics, Inc. (NEO) Q2 2024 Earnings Call Transcript
